Tag Archives: AXON

Analysts’ Perspective: PotlatchDeltic (PCH), Axon (AAXN), Shoe Carnival (SCVL)

Brokerage Firm BofA/Merrill upgraded PotlatchDeltic Corporation (NASDAQ:PCH) shares from Neutral to Buy rating.

PotlatchDeltic is a leading Real Estate Investment Trust that owns nearly 2 million acres of timberlands in Alabama, Arkansas, Idaho, Louisiana, Minnesota, and Mississippi.

*

Investment Analysts Dougherty & Company upgrade Axon Enterprise, Inc. (NASDAQ:AAXN) shares from Neutral to Buy rating with a price target of $67.

Axon Enterprise, Inc. develops, manufactures, and sells conducted energy weapons worldwide.

*

Shoe Carnival, Inc. (NASDAQ:SCVL) shares were upgraded by analysts at Sidoti from Neutral to Buy rating.

Shoe Carnival, Inc., together with its subsidiaries, operates as a family footwear in the United States.

**

Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE.Info is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://www.crwe.info/disclaimer/

Analysts’ Perspective: Orchard Therapeutics (ORTX), Axovant Sciences (AXON), Repligen (RGEN)

Investment Analysts at Goldman upgrade Orchard Therapeutics plc (NASDAQ:ORTX) shares from Neutral to Buy rating.

Orchard Therapeutics plc, an integrated biopharmaceutical company, focuses on developing various transformative treatments.

*

Brokerage Firm Jefferies upgraded Axovant Sciences Ltd. (NASDAQ:AXON) shares from Hold to Buy rating.

Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union.

*

Repligen Corporation (NASDAQ:RGEN) shares were upgraded by analysts at CL King from Neutral to Buy rating.

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide.

**

Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE.Info is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://www.crwe.info/disclaimer/